[Federal Register Volume 87, Number 110 (Wednesday, June 8, 2022)]
[Notices]
[Pages 34883-34884]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-12368]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2022-N-0691]


Advisory Committee; Peripheral and Central Nervous System Drugs 
Advisory Committee; Renewal

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; renewal of Federal advisory committee.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing the 
renewal of the Peripheral and Central Nervous System Drugs Advisory 
Committee by the Commissioner of Food and Drugs (the Commissioner). The 
Commissioner has determined that it is in the public interest to renew 
the Peripheral and Central Nervous System Drugs Advisory Committee for 
an additional 2 years beyond the charter expiration date. The new 
charter will be in effect until the June 4, 2024, expiration date.

DATES: Authority for the Peripheral and Central Nervous System Drugs 
Advisory Committee will expire on June 4, 2024, unless the Commissioner 
formally determines that renewal is in the public interest.

FOR FURTHER INFORMATION CONTACT: Jessica Seo, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring,

[[Page 34884]]

MD 20993-0002, 301-796-7699, email: <a href="/cdn-cgi/l/email-protection#7525363b26351311145b1d1d065b121a03"><span class="__cf_email__" data-cfemail="d484979a8794b2b0b5fabcbca7fab3bba2">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: Pursuant to 41 CFR 102-3.65 and approval by 
the Department of Health and Human Services and by the General Services 
Administration, FDA is announcing the renewal of the Peripheral and 
Central Nervous System Drugs Advisory Committee (the Committee). The 
Committee is a discretionary Federal advisory committee established to 
provide advice to the Commissioner. The Committee advises the 
Commissioner or designee in discharging responsibilities as they relate 
to helping to ensure safe and effective drugs for human use and, as 
required, any other product for which FDA has regulatory 
responsibility.
    The Committee reviews and evaluates data concerning the safety and 
effectiveness of marketed and investigational human drug products for 
use in the treatment of neurologic diseases.
    The Committee shall consist of a core of nine voting members, 
including the Chair. Members and the Chair are selected by the 
Commissioner or designee from among authorities knowledgeable in the 
fields of neurology, neuropharmacology, neuropathology, otolaryngology, 
epidemiology or statistics, and related specialties. Members will be 
invited to serve for overlapping terms of up to 4 years. Non-Federal 
members of this committee will serve as Special Government Employees, 
representatives or ex-officio members. Federal members will serve as 
Regular Government Employees or ex-officio members. The core of voting 
members may include one technically qualified member, selected by the 
Commissioner or designee, who is identified with consumer interests and 
is recommended by either a consortium of consumer-oriented 
organizations or other interested persons. In addition to the voting 
members, the Committee may include one non-voting representative member 
who is identified with industry interests. There may also be an 
alternate industry representative.
    Further information regarding the most recent charter and other 
information can be found at https://www.fda.gov/advisory-committees/peripheral-and-central-nervous-system-drugs-advisory-committee/peripheral-and-central-nervous-system-drugs-advisory-committee-charter 
or by contacting the Designated Federal Officer (see FOR FURTHER 
INFORMATION CONTACT). In light of the fact that no change has been made 
to the committee name or description of duties, no amendment will be 
made to 21 CFR 14.100.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app.). For general information related to FDA advisory 
committees, please visit us at https://www.fda.gov/AdvisoryCommittees/default.htm.

    Dated: June 3, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-12368 Filed 6-7-22; 8:45 am]
BILLING CODE 4164-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>